{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:01:26Z","timestamp":1761566486573,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jtho.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T23:15:11Z","timestamp":1661469311000},"page":"1067-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents"],"prefix":"10.1016","volume":"17","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2022.07.005_bib1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","article-title":"Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial","volume":"17","author":"Piccirillo","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","article-title":"Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study","volume":"151","author":"Yamamoto","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.07.005_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","article-title":"Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Kawashima","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2022.07.005_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2022.07.005_bib5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","article-title":"Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial","volume":"5","author":"Stinchcombe","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib7","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2217\/fon-2019-0400","article-title":"Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates","volume":"15","author":"Girard","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40801-021-00261-8","article-title":"European and US real-world treatment patterns in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective medical record review","volume":"8","author":"Shah","year":"2021","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jtho.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.2217\/fon-2020-0740","article-title":"Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study","volume":"16","author":"Hochmair","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2217\/fon-2020-0084","article-title":"Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study","volume":"16","author":"Girard","year":"2020","journal-title":"Future Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2022.07.005_bib13","article-title":"Amivantamab and lazertinib in patients with EGFR-mutant non\u2013small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2","volume":"40","author":"Shu","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2022.07.005_bib15","first-page":"S1283","article-title":"Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): TROPION-PanTumor01 Preliminary results from the phase I study","volume":"32","author":"Garon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"IMpower150 study group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2022.07.005_bib17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422003446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422003446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:26Z","timestamp":1761562166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422003446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1556086422003446"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.07.005","relation":{},"ISSN":["1556-0864"],"issn-type":[{"type":"print","value":"1556-0864"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.06.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}